Optimizing Anti-VEGF Treatment Outcomes in Neovascular AMD and DME

In this upcoming program, expert retina specialists discuss long-term experience with anti-VEGF therapies for age-related macular degeneration and diabetic macular edema, and share evidence-based strategies to improve treatment outcomes.

Related Videos
Related Content

Combination Therapy with Brolucizumab Appeared Well-Tolerated for nAMD Eyes

March 15th 2023

Arshad Khanani, MD: A Breakthrough in Geographic Atrophy Treatment

October 14th 2022

Identifying Risk Factors for AMD Progression Could Improve Clinical Outcomes

March 14th 2023

The Biggest Discussions in Retina from the 2022 ASRS Annual Meeting

July 20th 2022

Higher Risk of Developing Glaucoma Linked to Faster Rates of GCIPL Thinning

March 13th 2023

4 Geographic Atrophy Drug Classes Under Development

March 13th 2023

Combination Therapy with Brolucizumab Appeared Well-Tolerated for nAMD Eyes

March 15th 2023

Arshad Khanani, MD: A Breakthrough in Geographic Atrophy Treatment

October 14th 2022

Identifying Risk Factors for AMD Progression Could Improve Clinical Outcomes

March 14th 2023

The Biggest Discussions in Retina from the 2022 ASRS Annual Meeting

July 20th 2022

Higher Risk of Developing Glaucoma Linked to Faster Rates of GCIPL Thinning

March 13th 2023

4 Geographic Atrophy Drug Classes Under Development

March 13th 2023

Combination Therapy with Brolucizumab Appeared Well-Tolerated for nAMD Eyes

March 15th 2023

Arshad Khanani, MD: A Breakthrough in Geographic Atrophy Treatment

October 14th 2022

Identifying Risk Factors for AMD Progression Could Improve Clinical Outcomes

March 14th 2023

The Biggest Discussions in Retina from the 2022 ASRS Annual Meeting

July 20th 2022

Higher Risk of Developing Glaucoma Linked to Faster Rates of GCIPL Thinning

March 13th 2023

4 Geographic Atrophy Drug Classes Under Development

March 13th 2023
© 2023 MJH Life Sciences

All rights reserved.